Corticosteroid Co-Treatment and Chemotherapy Resistance in Pancreatic Cancer
Author Information
Author(s): Zhang Chengwen, Kolb Armin, Büchler Peter, Cato Andrew CB, Mattern Jürgen, Rittgen Werner, Edler Lutz, Debatin Klaus-Michael, Büchler Markus W, Friess Helmut, Herr Ingrid
Primary Institution: German Cancer Research Center
Hypothesis
Does dexamethasone induce resistance to chemotherapy in pancreatic cancer cells?
Conclusion
Dexamethasone induces therapy resistance in pancreatic carcinoma cells, raising concerns about its use in cancer treatment.
Supporting Evidence
- Dexamethasone inhibited drug-induced apoptosis in all examined malignant cells.
- In 18 of 20 cell lines from resected tumors, dexamethasone significantly prevented the cytotoxic effects of chemotherapy.
- In vivo, dexamethasone completely prevented the cytotoxicity of chemotherapy in xenografted pancreatic carcinoma cells.
Takeaway
Giving a medicine called dexamethasone with cancer treatment can make the cancer cells stronger and harder to kill.
Methodology
The study used pancreatic cancer cell lines, surgical resections, and xenografts in mice to assess the effects of dexamethasone on chemotherapy resistance.
Potential Biases
Potential bias due to the lack of randomized controlled trials evaluating the impact of glucocorticoids on solid tumors.
Limitations
The study did not correlate therapy resistance with patient demographics such as age, gender, or tumor stage.
Participant Demographics
Patients with pancreatic cancer, demographics not specified.
Statistical Information
P-Value
0.0063
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website